HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Poland Gives Green Light To Switches From Teva and Polpharma

Executive Summary

Teva and Polpharma's OTC operations in Poland are set to received a boost with the approval of two switches by national medicines regulator URPL. Polish consumers can now get OTC access to additional treatments for hay fever and cough. 

You may also be interested in...



Poland Switches from Rx-To-OTC Mylan's Duspatalin For IBS, Plus Orion's ED Treatment

Poland's medicines regulator has approved the switch of Mylan's Duspatalin and Orion's Valinger.

Bayer Launches Clarinaze Allergy Control Following Successful Rx-to-OTC Switch In UK

Having received the green light for its prescription-to-OTC switch, Bayer is launching in UK pharmacies Clarinaze Allergy Control backed by a £1m marketing campaign.

Poland Kick Starts 2019 With Three Rx-To-OTC Switches

Clotrimazole, pyrantel, and ciclopirox olamine have been switched from prescription-to-OTC status by Poland's national drug regulator.

Topics

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel